Regression may predict good prognosis in stage 1 and 2 cutaneous melanomas

Source: Healio, January 2021

Disease regression was associated with improved recurrence-free survival and overall survival among certain patients with stage 1 and 2 cutaneous melanomas, according to a study.

“Although regression is commonly observed in cutaneous melanoma, it is uncertain whether it is associated with patient prognosis,” Mary-Ann El Sharouni, MD, of the Melanoma Institute Australia at The University of Sydney and the department of dermatology at University Medical Center Utrecht at Utrecht University, the Netherlands, and colleagues wrote.

In the cohort study involving 17,271 Dutch patients and 4,980 Australian patients with stage 1 and 2 primary cutaneous melanomas, the researchers aimed to determine whether histologically confirmed regression was associated with better or worse survival.